# Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects

> **NCT01527643** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 30 (actual)

## Conditions studied

- Diabetes
- Healthy

## Interventions

- **DRUG:** biphasic insulin aspart 50

## Key facts

- **NCT ID:** NCT01527643
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11-11
- **Primary completion:** 2003-12-17
- **Final completion:** 2003-12-17
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01527643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01527643, "Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT01527643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*